Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01212380 · ClinicalTrials.gov registry record · Phase 1
Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL)
A Phase 1 study of Refractory Chronic Lymphocytic Leukemia and Recurrent Small Lymphocytic Lymphoma, sponsored by Ohio State University Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
- 1
- Study location
NCT01212380: Completed Phase 1 study of Refractory Chronic Lymphocytic Leukemia and Recurrent Small Lymphocytic Lymphoma, sponsored by Ohio State University Comprehensive Cancer Center.
NCT01212380 is a Phase 1 study of Refractory Chronic Lymphocytic Leukemia and Recurrent Small Lymphocytic Lymphoma that has completed, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 21 participants, below the 60-participant average among 19 other Refractory Chronic Lymphocytic Leukemia trials with a reported enrollment target (65% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01212380, a Phase 1 study of Refractory Chronic Lymphocytic Leukemia and Recurrent Small Lymphocytic Lymphoma, has completed, sponsored by Ohio State University Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
- 1
- Study location
Study Summary
RATIONALE: Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and the best dose of carfilzomib in treating patients with relapsed or refractory chronic lymphocytic leukemia(CLL),small lymphocytic lymphoma(SLL), or prolymphocytic leukemia (PLL).
Primary Outcome
The safe use of carfilzomib will be assessed by: * Determining the dose limiting toxicity and maximal tolerated dose of carfilzomib in patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL) and prolymphocytic leukemia (PLL) * To evaluating the toxicity profile of carfilzomib in relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL) and prolymphocytic leukemia (PLL)
Conditions Studied
Interventions
- DRUG carfilzomib
- OTHER Cytokine Assessment
- OTHER Pharmacodynamic Studies
- OTHER Proteosome Inhibition Assessment
- OTHER Pharmacogenomic Studies
Study Locations (1)
Ohio
- Ohio State University Medical Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2010-10 |
| Est. Completion | 2015-09 |
| Phase | Phase 1 |
What the finished NCT01212380 record still lists
NCT01212380 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 60-participant average among 19 other Refractory Chronic Lymphocytic Leukemia trials with a reported enrollment target (65% lower).
The record links to 5 conditions, with Refractory Chronic Lymphocytic Leukemia appearing as the primary indexed condition, and to 5 interventions - of which carfilzomib is the first listed.
NCT01212380 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT01212380 about?
NCT01212380 is a clinical study titled "Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL)". RATIONALE: Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and the best dose of carfilzomib in treating patients with relapsed or refractory chronic lymphocytic leukemia(CLL),small lym...
What is the current status of trial NCT01212380?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2010-10. Estimated completion is 2015-09.
What conditions does trial NCT01212380 study?
This clinical trial studies the following conditions: Refractory Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, B-cell Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Hematopoietic/Lymphoid Cancer.
What interventions are being tested in trial NCT01212380?
The interventions under investigation include: carfilzomib (DRUG), Cytokine Assessment (OTHER), Pharmacodynamic Studies (OTHER), Proteosome Inhibition Assessment (OTHER), Pharmacogenomic Studies (OTHER).
Who is sponsoring clinical trial NCT01212380?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01212380 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Refractory Chronic Lymphocytic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01212380's enrollment target sits among peer trials
21 14th of 19 higher than 6 of 19 other Refractory Chronic Lymphocytic Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Refractory Chronic Lymphocytic Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia
RECRUITING · Phase 1
-
B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies
RECRUITING · Phase 1
-
CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies
RECRUITING · Phase 1
-
Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia
ACTIVE NOT RECRUITING · Phase 1
-
Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma
ACTIVE NOT RECRUITING · Phase 1
-
Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia